As part of the $300 million takeover, shareholders will receive $4.40 in cash for each share of common stock, $517.65 in cash for each share of Series A Preferred Stock, and $172.01 for each share of Series B Preferred Stock.
Corixa is a biopharmaceutical company developing vaccine adjuvants and immunology based products that manage human diseases.